Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Eureka Therapeutics

- PMLiVE

Pfizer’s Elrexfio granted EC approval for relapsed and refractory multiple myeloma

More than 50,000 cases of the blood cancer are diagnosed each year in Europe

- PMLiVE

Sanofi and AI specialist Aqemia enter $140m drug discovery partnership

The deal is aimed at discovering small molecule drugs across several therapeutic areas

- PMLiVE

GSK shares positive phase 3 results for Blenrep combination in multiple myeloma

Approximately 176,000 new cases of multiple myeloma are diagnosed globally each year

- PMLiVE

Sanofi/Regeneron’s Dupixent shows promise in chronic obstructive pulmonary disease

About 300,000 people in the US have uncontrolled COPD and type 2 inflammation

- PMLiVE

Kite and Arcellx expand cell therapy partnership in deal worth over $285m

The companies' existing CART-ddBCMA collaboration now covers lymphomas

- PMLiVE

Sanofi partners with AI specialist BioMap in deal worth more than $1bn

The strategic collaboration is aimed at accelerating drug discovery for biotherapeutics

- PMLiVE

Sanofi and Teva to collaborate on inflammatory bowel disease drug in deal worth $1.5bn

About ten million people worldwide are affected by inflammatory bowel disease

- PMLiVE

Sanofi enters agreement with Janssen to develop E. coli vaccine candidate

Extraintestinal pathogenic E. coli is a leading cause of sepsis, particularly in older adults

- PMLiVE

Sanofi and Ad Scientiam partner to assess MS disability progression

The study will evaluate the ability of MSCopilot to identify early signs of disability worsening

- PMLiVE

Bristol Myers Squibb reveals plans to double number of drugs in registrational trials

The drugmaker expects to expand its research pipeline from six to 12 over next 18 months

- PMLiVE

Janssen’s Tecvayli approved by EC for reduced dosing frequency in multiple myeloma

Tecvayli was the first BCMA-targeting bispecific antibody to be approved in Europe

- PMLiVE

Janssen’s Talvey granted FDA accelerated approval for difficult-to-treat blood cancer

The therapy showed an overall response rate of more than 70% in a broad range of patients

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links